Literature DB >> 8752316

Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation.

R L Ullrich1, N D Bowles, L C Satterfield, C M Davis.   

Abstract

Variations in sensitivity to radiation-induced mammary cancer among different strains of mice are well known. However, the reasons for these variations have not been determined. In the present study, the cell dissociation assay was used to determine the radiation-induced transformation frequencies in sensitive BALB/c mice and resistant C57BL mice as well as the resistant hybrid B6CF1 independent of host environment. The influence of host environment on the progression of transformed cells to the neoplastic phenotype was also examined. Results demonstrated that the variations in sensitivity among these sensitive and resistant mice are a result of inherent differences in the sensitivity of the mammary epithelial cells to radiation-induced transformation. Under the conditions used, host environment played no role in the initiation of transformed cells by radiation or in the progression of these cells to the neoplastic phenotype.

Entities:  

Keywords:  Non-programmatic

Mesh:

Year:  1996        PMID: 8752316

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  19 in total

1.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Authors:  Shunbin Xiong; Vinod Pant; Yun Zhang; Neeraj K Aryal; M James You; Donna Kusewitt; Guillermina Lozano
Journal:  J Pathol       Date:  2017-01-06       Impact factor: 7.996

2.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 3.  Mouse models for radiation-induced cancers.

Authors:  Leena Rivina; Michael J Davoren; Robert H Schiestl
Journal:  Mutagenesis       Date:  2016-05-21       Impact factor: 3.000

4.  Influence of Hoxa5 on p53 tumorigenic outcome in mice.

Authors:  Gaëlle Gendronneau; Margot Lemieux; Mélanie Morneau; Josée Paradis; Bernard Têtu; Nancy Frenette; Josée Aubin; Lucie Jeannotte
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

Review 5.  Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.

Authors:  Mitchell E Menezes; Swadesh K Das; Luni Emdad; Jolene J Windle; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

6.  Telomere dysfunction and DNA-PKcs deficiency: characterization and consequence.

Authors:  Eli S Williams; Rebekah Klingler; Brian Ponnaiya; Tanja Hardt; Evelin Schrock; Susan P Lees-Miller; Katheryn Meek; Robert L Ullrich; Susan M Bailey
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

7.  Effect of low doses of low-let radiation on the innate anti-tumor reactions in radioresistant and radiosensitive mice.

Authors:  Ewa M Nowosielska; Aneta Cheda; Jolanta Wrembel-Wargocka; Marek K Janiak
Journal:  Dose Response       Date:  2012-08-30       Impact factor: 2.658

8.  Mutational Analysis of Ionizing Radiation Induced Neoplasms.

Authors:  Amy L Sherborne; Philip R Davidson; Katharine Yu; Alice O Nakamura; Mamunur Rashid; Jean L Nakamura
Journal:  Cell Rep       Date:  2015-09-03       Impact factor: 9.423

9.  CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.

Authors:  Xin-Hai Pei; Feng Bai; Matthew D Smith; Jerry Usary; Cheng Fan; Sung-Yun Pai; I-Cheng Ho; Charles M Perou; Yue Xiong
Journal:  Cancer Cell       Date:  2009-05-05       Impact factor: 31.743

Review 10.  Mouse models for efficacy testing of agents against radiation carcinogenesis—a literature review.

Authors:  Leena Rivina; Robert Schiestl
Journal:  Int J Environ Res Public Health       Date:  2012-12-27       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.